Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Bipolar Disorder is a chronic relapsing mental disorder characterized by periods of elevated,
expansive and irritable mood, often alternating with periods of significant clinical
depression. People with Bipolar Disorder are typically heavy smokers who have difficulty
quitting, and this is associated with significant tobacco-related medical illness and death.
The proposed study will be a double-blind, placebo-controlled 10-week clinical trial of the
safety and efficacy of varenicline (Champix™) in thirty subjects with Bipolar I Disorder.
This medication is the latest first-line pharmacotherapy for smoking cessation and has been
shown to be efficacious for smoking cessation, but has not yet been systematically studied in
persons with Bipolar Disorder.
Phase:
N/A
Details
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Tobacco Control Research Initiative